JP2025512999A5 - - Google Patents
Info
- Publication number
- JP2025512999A5 JP2025512999A5 JP2024559459A JP2024559459A JP2025512999A5 JP 2025512999 A5 JP2025512999 A5 JP 2025512999A5 JP 2024559459 A JP2024559459 A JP 2024559459A JP 2024559459 A JP2024559459 A JP 2024559459A JP 2025512999 A5 JP2025512999 A5 JP 2025512999A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- inhibitor
- adenocarcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329090P | 2022-04-08 | 2022-04-08 | |
| US63/329,090 | 2022-04-08 | ||
| PCT/US2023/015097 WO2023196086A2 (en) | 2022-04-08 | 2023-03-13 | Combination therapies comprising a sos1 inhibitor and an egfr inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512999A JP2025512999A (ja) | 2025-04-22 |
| JP2025512999A5 true JP2025512999A5 (https=) | 2026-03-25 |
Family
ID=88243368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559459A Pending JP2025512999A (ja) | 2022-04-08 | 2023-03-13 | Ｓｏｓ１阻害剤及びｅｇｆｒ阻害剤を含む併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250177410A1 (https=) |
| EP (1) | EP4504171A4 (https=) |
| JP (1) | JP2025512999A (https=) |
| KR (1) | KR20240170920A (https=) |
| CN (1) | CN119031916A (https=) |
| AU (1) | AU2023250819A1 (https=) |
| CA (1) | CA3245678A1 (https=) |
| IL (1) | IL315645A (https=) |
| MX (1) | MX2024012445A (https=) |
| WO (1) | WO2023196086A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022271679A1 (en) * | 2021-06-21 | 2022-12-29 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
| WO2025090810A1 (en) * | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Use of sos1 inhibitors and amivantamab to treat cancer |
| WO2025090808A1 (en) * | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Combinations of sos-1 inhibitors with osimertinib and/or met inhibitors to treat cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1833803A4 (en) * | 2005-01-03 | 2009-08-05 | Myriad Genetics Inc | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS AND THEIR USE |
| WO2016077793A1 (en) * | 2014-11-14 | 2016-05-19 | Children's Hospital Medical Center | Sos1 inhibitors for cancer treatment |
| EP3558979B1 (en) * | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| PH12022551513A1 (en) * | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2022083657A1 (zh) * | 2020-10-20 | 2022-04-28 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
| CA3221608A1 (en) * | 2021-06-14 | 2022-12-22 | Kumquat Biosciences Inc. | Fused heteroaryl compounds useful as anticancer agents |
-
2023
- 2023-03-13 CN CN202380032772.0A patent/CN119031916A/zh active Pending
- 2023-03-13 IL IL315645A patent/IL315645A/en unknown
- 2023-03-13 AU AU2023250819A patent/AU2023250819A1/en active Pending
- 2023-03-13 CA CA3245678A patent/CA3245678A1/en active Pending
- 2023-03-13 JP JP2024559459A patent/JP2025512999A/ja active Pending
- 2023-03-13 WO PCT/US2023/015097 patent/WO2023196086A2/en not_active Ceased
- 2023-03-13 KR KR1020247033657A patent/KR20240170920A/ko active Pending
- 2023-03-13 EP EP23785156.3A patent/EP4504171A4/en active Pending
- 2023-03-13 US US18/851,642 patent/US20250177410A1/en active Pending
-
2024
- 2024-10-07 MX MX2024012445A patent/MX2024012445A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024537140A5 (https=) | ||
| JP2025512999A5 (https=) | ||
| JP2022548791A5 (https=) | ||
| JP2025000632A5 (https=) | ||
| JP2024537136A5 (https=) | ||
| JP2025000629A5 (https=) | ||
| JP2024521788A5 (https=) | ||
| JP2024537139A5 (https=) | ||
| JP2025000630A5 (https=) | ||
| FI3849537T3 (fi) | Yhdistelmäterapioita | |
| JP2024537137A5 (https=) | ||
| JP2022548255A5 (https=) | ||
| JP2023540809A5 (https=) | ||
| JP2022549375A5 (https=) | ||
| JP2024540839A5 (https=) | ||
| JP2025506408A5 (https=) | ||
| Kojonazarov et al. | Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling | |
| JP2022530866A5 (https=) | ||
| JP2022509724A5 (https=) | ||
| IL274601B1 (en) | Kras g12c inhibitors | |
| JP2022535577A5 (https=) | ||
| IL315645A (en) | Combination therapies comprising a sos1 inhibitor and an egfr inhibitor | |
| IL311834A (en) | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods | |
| JP2022500388A5 (https=) | ||
| IL311863A (en) | Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods |